Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-200-5 | CAS number: 1312-81-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Some information in this page has been claimed confidential.
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2006
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- yes
- Remarks:
- 2 out of 6 analytical investigation of the dosage formulations were conducted under non-GLP conditions
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- yes
- Remarks:
- 2 out of 6 analytical investigation of the dosage formulations were conducted under non-GLP conditions
- Limit test:
- no
Test material
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
Results and discussion
Results of examinations
- Details on results:
- ANALYSIS OF TEST SUBSTANCE IN VEHICLE
Homogeneity and stability of the test compound in the diet were checked prior to study start. These analytical investigation showed the test compound to be homogeneously distributed and stable in the concentration range used beyond the period of use. Analyses during the study verified that the test compound content agreed with the target concentrations and that the test compound was homogeneously distributed in the diet within the defined limits (Table 1)
CLINICAL SIGNS AND MORTALITY
- Loss of hair was observed in control animals (1 male, 3 females). Tilted head was observed in 2 males and 2 females of the 1400 ppm group and in 2 males of the 14000 ppm group. No other clinical signs were observed in any animal.
- Survival was not affected by the treatment with the test compound since all animals survived until scheduled day of sacrifiec
BODY WEIGHT AND WEIGHT GAIN
Body weight development was unaffected in all treated animals (Table 2). The slightly lower body weight in 1400 ppm and 14000 ppm females compared to control is not considered to be adverse (at the end of treatment: 4%, 6%) as there was no dose dependency. A transient body weight reduction from day 29 to 36 and from day 85 to 92, could be observed in all groups (females: delayed body weight gain) and was likely caused by blood and urine sampling, respectively.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
- Food intake per animal and per kg body weight of all treated animals was comparable to the respective controls (Table 3).
- The mean daily test compound intake with the food over 13 weeks, in order of ascending dosages, was 94.0, 276.1, 974.2 mg/kg body weight in males and 135.1, 391.2 and 1480.4 mg/kg body weight in females. The test compound intake was comparable to the theoretical dose interval (Table 3).
WATER CONSUMPTION
Water intake per animal and per kg body weight of all treated animals was unaffected compared to controls (Table 4).
OPHTHALMOSCOPIC EXAMINATION
At study start no ophthalmological findings were seen. The examinations at termination gave no evidence for treatment-related effects. Isolated findings (reduced pupillary reflex, opacity changes of the lens) in all dose groups were regarded as spontaneous and gave no indication of a treatment effect.
HAEMATOLOGY
Hematological investigation revealed no treatment-related changes of parameters of white and red blood count as well as blood coagulation (Table 5 and 6).
The decreased mean erythrocyte count in males (day 92) at 1400 ppm, decreased hematocrit and increased mean corpuscular hemoglobin concentration in males at 1400 and 4200 ppm (day 92) as well as decreased thrombocyte count in males at 14000 ppm on day 36 and 92 (on day 92 also at 4200 ppm), which were statistically significantly different from control values are considered to be of no toxicological relevance, since they did not show a correlation with the dose administered and / or with the time of treatment and the differences from control were low.
In one female (14000 ppm) several parameters of the white blood counts were increased on day 91: leucocytes, neutrophils, lymphocytes, monocytes, eosinophils, and basophils (values out of the 2s range of historical data). The histopathology evidenced an early tumor of the hematopoietic system in this animal. This animal was excluded with regard to the evaluation of these haematological parameters. However, even before excluding, no statistically significantly changes were observed in mean differential blood count
CLINICAL CHEMISTRY
Determination of enzyme activities in peripheral blood showed no toxicologically relevant changes of enzyme activities compared to control values (Tables 7 - 9). Statistically significantly higher activities of glutamate dehydrogenase (GLDH) in males at 1400 ppm were considered as incidental, since no dose response was evident.
Increased cholesterol concentrations were measured in males at 1400 ppm, total protein and albumin concentrations in males at 4200 ppm and creatinine concentrations in females at 14000 ppm (all findings on day 35/36; p<=0.05). Furthermore, reduced cholesterol concentrations (day 35 and 91) and triglyceride concentration (day 35) were seen in 14000 ppm females (each p>0.05). These findings are considered to be of no toxicological relevance since the differences from control were low and/or they did not show a correlation with the dose administered and/or with the time of treatment. The concentration of urea was increased in 4 of 10 females at 14000 ppm on day 91. However, these values were not statistically significant, but exceeded the range of historical data.
Sodium was decreased in 1400 ppm males and above (day 36; 14000 ppm: p>0.05) and increased in 4200 ppm males (day 92), calcium was decreased in 1400 ppm males and above (day 36), inorganic phosphate was increased in 4200 ppm males (day 92), and chloride was increased in 14000 ppm females (day 35; all p<=0.05). These findings are considered to be of no toxicological relevance, since the differences from controls were low and/or did not show a correlation with the dose administered and/or with the time of treatment.
URINALYSIS
Urine volumes and densities as well as excreted amounts of urea and creatinine were comparable in treated animals and controls (Table 10).Excretion of protein and protein/creatinine ratio were increased in females at 4200 ppm (p>0.05). This increase was however due to the values of only one animal of this group. E ven before excluding this animal, no statistically significantly changes were observed for these parameters. Therefore, for these (not dose-dependent) isolated higher parameters are considered toxicologically not relevant.
The semi-quantitatively determined blood, bilirubin, glucose, urobilinogen, and ketone body concentrations and also the pH values were unremarkable in all groups. The sediments showed no abnormalities in males or females
NEUROBEHAVIOUR
- FOB: alopecia was observed in control animals (1 male, 4 females). Furthermore, single animals showed tilted head, but without dose dependency (0, 1400, 4200, 14000 ppm): 0-2-1-1 in males, 0-0-1-0 in females (Table 11). The number of rearing counts was slightly higher compared to controls in 4200 ppm females and 14000 ppm male and female rats.
- Motor Activity Assessment: The activity determination over the entire 60 minute observation period failed to reveal a significant effect on motor (MA) and locomotor activity (LMA). The results of the 10-minute intervals indicate that treated and control groups reacted in a similar way. In particular, there were no significant differences in the first 10-minute intervals which are regarded as best indicator of increases or decreases in activity before the animals habituate to a minimal level of activity (Table 11).
BIOCHEMICAL LIVER PARAMETERS
The investigation in liver tissue showed slightly increased activities of p-Nitroanisole-O-Demethylase in males at 1400 ppm and above (p<= 0.01; Table 12). Because a clear dose response was missing and all individual data of dosed animals were within the range of historical data and furthermore, in 1 of the 10 control animals the individual value was below this range, these findings were considered to be incidental and rather related to low control values. The slightly decreased activity of aminopyrine-N-Demethylase (N-DEM) in males at 1400 ppm (p<=0.05) was considered to be of no toxicological relevance since dose correlation was absent.
IMMUNOTOXICITY
- Cell count: The immunotoxicological examinations of the main group animals at the end of the study period revealed no evidence of treatment-related effects (Table 13). Regarding splenic cell counts there were no compound induced effects in both sexes up to 14000 ppm.
- FACS scan analysis: statistically significant decreases of total CD4 cells starting at 4200 ppm and CD45 positive cells at the lower doses 1400 and 4200 ppm were found in males. While CD45 low positive cells were slightly increased at 4200 ppm and above, CD45 high cells were statistically significant reduced in all test item treated groups. These statistically significant changes in males were within the normal range of variance for these parameter, and are thus of no biological relevance. In females only one single statistically significant increase was detected for CD45 low positive cells at
14000 ppm. This increase is within the range of normal variance of this parameter, and is thus of no biological relevance.
- Antibody titer: There was a statistically significant decrease for the antibody titer of IgA in males at 4200 ppm and above (Table 14). These changes were not dose dependent, not corroborated in the other gender (female), and within the range of normal variance for this parameter. Therefore, this change should not be judged as an adverse effect. The females showed no statistically significant changes in any titer of total Ig.
- Plaque forming cell assay: the immunotoxicological examinations of the Plaque Forming Cell Assay revealed no evidence of treatment-related effects although male rats showed a statistically significant decrease of the splenic cell counts at 4200 ppm (Table 15). This has to be seen as an isolated finding which is not corroborated by a finding in the other gender or after a 90 day treatment period. Furthermore, this decrease was within the normal range of variance for this parameter. Regarding splenic cell counts female rats showed no substance induced effects up to and including 14000 ppm.
ORGAN WEIGHTS
The determination of the weights of the organs gave no evidence for treatment-related effects (Table 16).
GROSS PATHOLOGY
Necropsy revealed no evidence of any treatment related gross lesion.
HISTOPATHOLOGY: NON-NEOPLASTIC
The histopathological evaluation revealed no treatment-related findings. All observations occurred at a comparable frequency and severity grade among control and dosed animals.
HISTOPATHOLOGY: NEOPLASTIC
An early tumor of the hematopoietic system (granulocytic leukemia) in one high dose female was found which showed increased numbers of leucocytes. Since none of the clinical chemical or hematological parameters in the remaining animals gave any indication for a compound-related effect, the occurrence of this tumor is considered as an incidental event. No other neoplastic findings were noted.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 14 000 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Original nominal value according to the test substance lanthanumcarbonate-octahydrate.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 974 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Original value (mean daily intake) according to the test substance lanthanumcarbonate-octahydrate.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 480 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Original value (mean daily intake) according to the test substance lanthanumcarbonate-octahydrate.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 6 440 ppm
- Based on:
- element
- Sex:
- male/female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 448 mg/kg bw/day (actual dose received)
- Based on:
- element
- Sex:
- male
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 681 ppm
- Based on:
- element
- Sex:
- female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La
- Dose descriptor:
- NOAEL
- Effect level:
- >= 7 553 ppm
- Based on:
- other: La2O3
- Sex:
- male/female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La2O3
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 525 mg/kg bw/day (actual dose received)
- Based on:
- other: La2O3
- Sex:
- male
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La2O3
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 799 mg/kg bw/day (actual dose received)
- Based on:
- other: La2O3
- Sex:
- female
- Basis for effect level:
- other: Overall effects: no adverse treatment-related effects were noted. Recalculated value for La2O3
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
For result tables 1 - 16 see attached document.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Although ECHA is providing a lot of online material in your language, part of this page is only in English. More about ECHA’s multilingual practice.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
the-echa-website-uses-cookies
find-out-more-on how-we-use-cookies